# Nicolino Ruperto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nicolino-ruperto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,427 |
| Field | Autoimmune and Inflammatory Disorders Research |
| h-index | 94 |
| i10-index | 285 |
| OpenAlex ID | https://openalex.org/A5080140512 |
| ORCID iD | https://orcid.org/0000-0001-8407-7782 |
| Works | 674 |

## Researcher papers

- [2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative](https://scholariq.org/papers/2016-classification-criteria-for-macrophage-activation-syndrome-complicating/)
- [Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C‐HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF‐36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index‐2 (FI‐2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)](https://scholariq.org/papers/measures-of-adult-and-juvenile-dermatomyositis-polymyositis-and-inclusion-body/)
- [2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis](https://scholariq.org/papers/2016-classification-criteria-for-macrophage-activation-syndrome-complicating-2/)
- [EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation](https://scholariq.org/papers/eular-printo-pres-criteria-for-henoch-schonlein-purpura-childhood-polyarteritis/)
- [Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial](https://scholariq.org/papers/safety-and-efficacy-of-intravenous-belimumab-in-children-with-systemic-lupus/)
- [Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension](https://scholariq.org/papers/long-term-efficacy-and-safety-of-infliximab-plus-methotrexate-for-the-treatment/)

## Researcher topics

- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Adolescent and Pediatric Healthcare](https://scholariq.org/topics/adolescent-and-pediatric-healthcare/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Inflammasome and immune disorders](https://scholariq.org/topics/inflammasome-and-immune-disorders/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.